Clinical Trials Logo

Head and Neck Carcinoma clinical trials

View clinical trials related to Head and Neck Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06289049 Not yet recruiting - Clinical trials for Head and Neck Cancer

Heavy Strength Training in Head and Neck Cancer Survivors

LIFTING2
Start date: April 2024
Phase: Phase 2
Study type: Interventional

Despite improvements in treatments, head and neck cancer survivors (HNCS) still endure acute and chronic side effects such as loss of muscular strength, limitations in physical functioning, fatigue, and swallowing difficulties that impact quality of life (QoL) and limit return to work. Light-to-moderate intensity strength training (LMST) has been shown to improve some side effects. Heavy lifting strength training (HLST) may further improve outcomes in some populations, however, only one small pilot study has focused on HNCS. The LIFTING 2 trial will be the first to examine the feasibility and effects of a HLST program versus no exercise in HNCS.

NCT ID: NCT05073172 Not yet recruiting - Breast Carcinoma Clinical Trials

StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy.

NCT ID: NCT03591666 Not yet recruiting - Adenocarcinoma Clinical Trials

A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Start date: July 15, 2018
Phase: Phase 2
Study type: Interventional

This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.